巨噬细胞
炎症
移植
心脏移植
医学
微循环
纤维化
免疫系统
移植排斥反应
癌症研究
心脏纤维化
血管生成
免疫学
化学
细胞生物学
细胞疗法
体内
内皮干细胞
细胞
免疫疗法
转染
M2巨噬细胞
新生血管
药物输送
作者
Haichao Yang,Haobo Yang,Jinhong Liu,Jie Chen,Cong Liu,Jiaxu Wang,Jiaxin Shan,Mingyuan Xu,Guangyin Li,Ye Yao,Sirui Tian,Chen Zhao,T. Zhang,Li Yin,Yangyang Tao,Dandan Yu,Shouqiang Li,Zhuo Wang,Xiaoping Leng
标识
DOI:10.1002/adhm.202505516
摘要
ABSTRACT Rejection following heart transplantation remains a significant challenge in the medical science. In addition to the immune response, the inflammatory response and microvascular endothelial damage can exacerbate rejection; however, current therapies focus primarily on the immune response. Numerous studies have confirmed that miR‐126 regulates vascular inflammation and promotes angiogenesis. To achieve the precise targeted delivery of miR‐126, macrophage biomimetic ultrasound phase‐change cationic nanoparticles carrying miR‐126 (miR‐126‐MCNPs) are synthesized. Incorporation of the macrophage membrane enhances the anti‐phagocytic and inflammatory targeting of nanoparticles, thereby prolonging the circulation time and promoting aggregation in the transplanted heart. Using ultrasound‐targeted microbubble destruction (UTMD), the perfluoropentane nanoparticle core undergoes a phase change in the ultrasound irradiation zone, allowing the targeted delivery of macrophage membranes and miR‐126, and significantly improving the transfection efficiency of the miR‐126. Consequently, anti‐inflammatory effects are achieved, such as inhibition of macrophage and CD3 + T cells infiltration, and alteration of M2‐type macrophage differentiation. In addition, this study demonstrates that the combination of miR‐126‐MCNPs with UTMD can alleviate the extent of vascular endothelial and interstitial fibrosis in transplanted hearts, increase angiogenesis, and improve microcirculation and cardiac function. This research provides a new strategy for the precision‐targeted therapy of cardiac transplant rejection.
科研通智能强力驱动
Strongly Powered by AbleSci AI